ZOVIRAX TABLET 800 mg (DISPERSIBLE)

Země: Singapur

Jazyk: angličtina

Zdroj: HSA (Health Sciences Authority)

Aktivní složka:

ACICLOVIR

Dostupné s:

GLAXOSMITHKLINE PTE LTD

ATC kód:

J05AB01

Léková forma:

TABLET, FILM COATED

Složení:

ACICLOVIR 800 mg

Podání:

ORAL

Druh předpisu:

Prescription Only

Výrobce:

Glaxo Wellcome, S.A.

Stav Autorizace:

ACTIVE

Datum autorizace:

1995-04-11

Charakteristika produktu

1
ZOVIRAX
Oral Formulations
ACICLOVIR
QUALITATIVE AND QUANTITATIVE COMPOSITION
Tablets:
Zovirax Tablets 200mg are white, round, biconvex tablets impressed
“GXCL3” on one side and
plain on the other, each tablet containing 200mg aciclovir.
Zovirax Dispersible Tablets 800mg are white, film-coated oval biconvex
tablets, branded
“GXCG1” on one face and plain on the other and contain 800mg
aciclovir in each tablet.
Oral Suspension:
Zovirax Suspension 200mg/5mL is a white, banana-flavoured, oral
suspension containing 200mg
aciclovir in each 5mL.
CLINICAL INFORMATION
INDICATIONS
Zovirax Oral Formulations are indicated for the treatment of Herpes
simplex virus infections of
the skin and mucous membranes, including initial and recurrent genital
herpes.
Zovirax Oral Formulations are indicated for the suppression
(prevention of recurrence) of
recurrent Herpes simplex infections in immune-competent patients.
Zovirax Oral Formulations are indicated for the prophylaxis of Herpes
simplex infections in
immune-compromised patients.
Zovirax Oral Formulations are indicated for treatment of Varicella
(Chickenpox) and Herpes
zoster (Shingles) infections. Studies have shown that early treatment
of shingles with Zovirax
2
has a beneficial effect on pain and can reduce the incidence of
post-herpetic neuralgia (zoster-
associated pain).
DOSAGE AND ADMINISTRATION
_Pharmaceutical Form: _
Tablets.
Dispersible tablets.
Oral suspension.
_Dosage for treatment of Herpes simplex in adults _
_ _
For the treatment of Herpes simplex infections, 200mg Zovirax should
be taken five times daily
at approximately four-hourly intervals omitting the night time dose.
Treatment should continue
for five days but in severe initial infections may have to be
extended.
In severely immune-compromised patients (e.g., after marrow
transplant) or in patients with
impaired absorption from the gut the dose can be doubled to 400mg or,
alternatively, intravenous
dosing could be considered.
Dosing should begin as early as possible after the start of an
infection;